بانک مقالات

بهینه سازی درمان کیلاسیون آهن با دیفرازیراکس برای بیماران تالاسمی بدون وابستگی به انتقال خون: مطالعه نتایج 1 سال از THETIS

Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study

سال انتشار : 2016

تعداد صفحه : 7

کلیدواژه ها: Non-transfusion-dependent thalassaemia, NTDT, Iron overload, Iron chelation therapy, Dose escalation

   دانلود    سفارش ترجمه

ABSTRACT

Efficacy and safety of iron chelation therapy with deferasirox in iron-overloaded non-transfusion-dependent thalassaemia (NTDT) patients were established in the THALASSA study. THETIS, an open-label, single-arm, multicentre, Phase IV study, added to this evidence by investigating earlier dose escalation by baseline liver iron concentration (LIC) (week 4: escalation according to baseline LIC; week 24: adjustment according to LIC response, maximum 30 mg/kg/day). The primary efficacy endpoint was absolute change in LIC from baseline to week 52. 134 iron-overloaded non-transfusion-dependent anaemia patients were enrolled and received deferasirox starting at 10 mg/kg/day. Mean actual dose ± SD over 1 year was 14.70 ± 5.48 mg/kg/day. At week 52, mean LIC ± SD decreased significantly from 15.13 ± 10.72 mg Fe/g dw at baseline to 8.46 ± 6.25 mg Fe/g dw (absolute change from baseline, −6.68 ± 7.02 mg Fe/g dw [95% CI: −7.91, −5.45]; P b 0.0001). Most common drug-related adverse events were gastrointestinal: abdominal discomfort, diarrhoea and nausea (n = 6 each). There was one death (pneumonia, not considered drug related). With significant and clinically relevant reductions in iron burden alongside a safety profile similar to that in THALASSA, these data support earlier escalation with higher deferasirox doses in iron-overloaded non-transfusion-dependent anaemia patients.

زبان فایل

مجلات و ژورنال های بین المللی

Elsevier

ترجمه

نوع فایل

رایگان

سال انتشار

2016

دیدگاهها

هیچ دیدگاهی برای این محصول نوشته نشده است.

اولین نفری باشید که دیدگاهی را ارسال می کنید برای “بهینه سازی درمان کیلاسیون آهن با دیفرازیراکس برای بیماران تالاسمی بدون وابستگی به انتقال خون: مطالعه نتایج 1 سال از THETIS”

نشانی ایمیل شما منتشر نخواهد شد. بخش‌های موردنیاز علامت‌گذاری شده‌اند *